DCT

1:25-cv-00861

PH Health Ltd v. Baxter Healthcare Corp

Log In
Key Events
Amended Complaint
complaint Intelligence

I. Executive Summary and Procedural Information

  • Parties & Counsel:
  • Case Identification: 1:25-cv-00861, D. Del., 09/11/2026
  • Venue Allegations: Venue is alleged to be proper in the District of Delaware as Defendant is a Delaware corporation and is subject to personal jurisdiction in the district, having maintained continuous and systematic contacts, transacted business, and derived substantial revenue from sales within the district.
  • Core Dispute: Plaintiffs allege that Defendant's submission of a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) for a generic epinephrine injection product constitutes an act of infringement of five U.S. patents directed to stable, ready-to-administer epinephrine formulations.
  • Technical Context: The technology concerns ready-to-use, low-concentration, premixed intravenous (IV) bags of epinephrine, developed to improve stability and overcome the risks of dilution errors and microbial contamination associated with traditional concentrated epinephrine vials.
  • Key Procedural History: This is a Hatch-Waxman action initiated after Defendant, Baxter Healthcare Corporation, sent Plaintiffs a Notice Letter dated May 29, 2025, containing a Paragraph IV Certification against the patents-in-suit. The certification states that the patents are invalid, unenforceable, and/or will not be infringed by Baxter's proposed product. The action was commenced within the 45-day statutory window. This filing is a Second Amended Complaint.

Case Timeline

Date Event
2012-12-07 FDA approval of Adrenalin® single-dose vials (NDA No. 204200)
2012-12-18 FDA approval of Adrenalin® multi-dose vials (NDA No. 204640)
2018-03-23 Earliest Priority Date for all Patents-in-Suit
2020-03-19 U.S. Patent No. 10,653,646 Issued
2021-07-27 U.S. Patent No. 11,071,719 Issued
2021-08-10 U.S. Patent No. 11,083,698 Issued
2021-12-28 U.S. Patent No. 11,207,280 Issued
2023-05-10 ’646, ’280, and ’698 patents listed in FDA Orange Book
2024-11-05 U.S. Patent No. 12,133,837 Issued
2024-11-06 ’837 patent listed in FDA Orange Book
2025-05-29 Date of Defendant's Notice Letter
2026-03-16 Alleged FDA approval date for Defendant's sNDA
2026-09-11 Second Amended Complaint Filed

II. Technology and Patent(s)-in-Suit Analysis

U.S. Patent No. 11,071,719 - “Epinephrine Compositions and Containers”

The Invention Explained

  • Problem Addressed: The patent addresses the instability of epinephrine in aqueous solutions, which deteriorates rapidly through oxidation and racemization, especially when diluted for administration Compl. ¶¶35-36 This instability leads to a short shelf-life and risks of dilution errors and contamination when prepared in a clinical setting from concentrated forms (’719 Patent, col. 1:45-58).
  • The Patented Solution: The patent describes a method for producing a stable, low-concentration, ready-to-inject epinephrine formulation that is substantially free of antioxidants ’719 Patent, abstract The method involves combining epinephrine with an aqueous carrier, adjusting the pH to a specific range (3.0-4.7), including a metal ion chelator, packaging the composition under an inert gas, and sterilizing it, often via autoclaving ’719 Patent, col. 4:17-49 This process is designed to minimize both degradation and racemization into the inactive S-isomer, resulting in a product with improved shelf stability.
  • Technical Importance: This method allows for the manufacture of the first FDA-approved, manufacturer-prepared, premixed intravenous (IV) bag of epinephrine, enhancing patient safety and convenience in clinical settings Compl. ¶39

Key Claims at a Glance

  • The complaint alleges infringement of one or more claims of the ’719 patent Compl. ¶50
  • Independent claim 1 recites a method of producing a storage stable ready-to-inject epinephrine composition, with the essential elements including:
    • Combining an aqueous carrier with epinephrine to a concentration of ≤ 0.07 mg/mL.
    • The carrier having dissolved oxygen of ≤ 2 ppm.
    • Adjusting the pH to between 3.0-4.7.
    • Including a metal ion chelator (EDTA, EGTA, or DTPA) at a concentration between about 1 and 50 mcg/mL.
    • Packaging the composition into a container under an inert gas.
    • Sterilizing the composition.
    • Resulting in a composition that is substantially antioxidant-free and has, after one month of storage, total impurities ≤ 0.7% and S-isomer content ≤ 4%.
  • The complaint does not specify dependent claims but reserves the right to assert additional claims Compl. ¶49

U.S. Patent No. 11,207,280 - “Epinephrine Compositions and Containers”

The Invention Explained

  • Problem Addressed: As with the related patents, the ’280 patent addresses the chemical instability (oxidation and racemization) of diluted epinephrine solutions, which limits their shelf-life and creates risks of dosage errors when prepared from concentrates ’280 Patent, col. 1:45-58 Compl. ¶¶35-36
  • The Patented Solution: The patent claims a specific sterile, ready-to-inject epinephrine composition that is substantially antioxidant-free ’280 Patent, abstract The composition achieves stability through a combination of a low epinephrine concentration, a controlled pH range, the inclusion of a metal ion chelator, and a low level of dissolved oxygen, all packaged in a container suitable for sterile administration ’280 Patent, col. 3:1-9 ’280 Patent, col. 5:46-56
  • Technical Importance: The claimed composition provides a safe, stable, and convenient premixed epinephrine product, eliminating the need for bedside dilution and its associated risks Compl. ¶39

Key Claims at a Glance

  • The complaint alleges infringement of one or more claims of the ’280 patent Compl. ¶58
  • Independent claim 1 recites a sterile storage stable ready-to-inject epinephrine composition, with the essential elements including:
    • An aqueous carrier containing epinephrine at a concentration of ≤ 0.07 mg/ml.
    • At least 90 mol % of the epinephrine is the R-isomer.
    • A pH between 3.0-4.7.
    • A metal ion chelator (bicarboxylic acid, tricarboxylic acid, or aminopolycarboxylic acid) at a concentration between 1 and 50 µg/ml.
    • Total impurities of ≤ 0.3% after one month of storage at 25° C.
  • The complaint does not specify dependent claims but reserves the right to assert additional claims Compl. ¶57

U.S. Patent No. 12,133,837 - “Epinephrine Compositions and Containers”

  • Patent Identification: U.S. Patent No. 12,133,837, “Epinephrine Compositions and Containers,” issued November 5, 2024 Compl. ¶23
  • Technology Synopsis: The patent claims a sterile, ready-to-inject epinephrine composition with specific stability characteristics. It addresses the problem of epinephrine degradation by defining a composition with a low impurity profile and S-isomer content after a specified storage period, achieved through a controlled pH and the use of a metal ion chelator in a substantially antioxidant-free formulation ’837 Patent, abstract ’837 Patent, claim 1
  • Asserted Claims: One or more claims, including independent claims 1 and 10 Compl. ¶66
  • Accused Features: Defendant's Proposed sNDA Product, an epinephrine injection, is alleged to be a composition covered by the patent claims Compl. ¶66

U.S. Patent No. 10,653,646 - “Epinephrine Compositions and Containers”

  • Patent Identification: U.S. Patent No. 10,653,646, “Epinephrine Compositions and Containers,” issued March 19, 2020 Compl. ¶26
  • Technology Synopsis: The patent claims an antioxidant-free, storage-stable, ready-to-inject epinephrine composition. The invention solves the problem of epinephrine instability by specifying a composition with a particular pH range (3.0-4.7), a metal ion chelator concentration (1-50 µg/ml), and defined limits on total impurities and S-isomer content after at least one month of storage ’646 Patent, abstract ’646 Patent, claim 1
  • Asserted Claims: One or more claims, including independent claim 1 Compl. ¶74
  • Accused Features: Defendant's Proposed sNDA Product, an epinephrine injection, is alleged to be a composition that meets the claimed limitations Compl. ¶74

U.S. Patent No. 11,083,698 - “Epinephrine Compositions and Containers”

  • Patent Identification: U.S. Patent No. 11,083,698, “Epinephrine Compositions and Containers,” issued August 10, 2021 Compl. ¶29
  • Technology Synopsis: This patent is directed to a method of administering epinephrine by providing a specific antioxidant-free, sterile epinephrine composition and injecting it without prior dilution. It solves the clinical problem of dosing errors by providing a ready-to-use formulation whose stability is ensured by a specific pH, a metal ion chelator, and defined impurity limits after storage ’698 Patent, abstract ’698 Patent, claim 1
  • Asserted Claims: One or more claims, including independent claims 1 and 13 Compl. ¶82
  • Accused Features: Defendant's Proposed sNDA Product, which Plaintiffs allege will be administered according to its label, is accused of infringing the claimed method Compl. ¶82 Compl. ¶84

III. The Accused Instrumentality

Product Identification

Baxter's Epinephrine in 0.9% Sodium Chloride Injection, 4 mg/250 mL (16 mcg/mL), referred to as the "Proposed sNDA Product" Compl. ¶1

Functionality and Market Context

The accused product is a premixed, injectable epinephrine solution submitted for FDA approval via an sNDA Compl. ¶1 The complaint alleges that the product is intended for the same indication as Plaintiffs' Adrenalin® bags: to increase mean arterial blood pressure in adult patients with hypotension associated with septic shock Compl. ¶32 Compl. ¶44 The complaint further alleges that Defendant's sNDA relies on data demonstrating the bioequivalence of the Proposed sNDA Product to Plaintiffs' Adrenalin® product Compl. ¶43 No probative visual evidence provided in complaint.

IV. Analysis of Infringement Allegations

The complaint alleges infringement under 35 U.S.C. § 271(e)(2), which defines the submission of an ANDA or sNDA seeking approval to market a generic drug before patent expiration as a statutory act of infringement. The infringement allegations are premised on the belief that the product described in Defendant's sNDA, if manufactured and sold, would infringe the patents-in-suit Compl. ¶51 Compl. ¶58 The complaint notes that Defendant's Notice Letter provided only conclusory arguments of non-infringement and that full details are unavailable pending discovery Compl. ¶49

’719 Patent Infringement Allegations

Claim Element (from Independent Claim 1) Alleged Infringing Functionality Complaint Citation Patent Citation
A method of producing a storage stable ready-to-inject epinephrine composition, comprising: combining an aqueous pharmaceutically acceptable carrier with epinephrine in an amount such that the epinephrine is present in the ready-to-inject epinephrine composition at a concentration of equal or less than 0.07 mg/mL... The complaint alleges Defendant seeks approval to manufacture a product with an epinephrine concentration of 16 mcg/mL (0.016 mg/mL). ¶42 col. 4:19-23
...wherein the aqueous pharmaceutically acceptable carrier has dissolved oxygen in an amount of equal or less than 2 ppm; The complaint does not provide specific detail on the manufacturing process but alleges the final product infringes the claims. ¶50 col. 4:24-26
adjusting the pH of the ready-to-inject epinephrine composition to a pH of between 3.0-4.7; The Proposed sNDA Product is alleged to be covered by the claims, which require this specific pH range. ¶42 col. 4:27-29
including into the ready-to-inject epinephrine composition a metal ion chelator selected from the group consisting of EDTA...at a concentration of between about 1 and 50 mcg/mL; The Proposed sNDA Product is alleged to be covered by the claims, which require this specific chelator and concentration. ¶42 col. 4:30-36
packaging the ready-to-inject epinephrine composition into a container under an inert gas; and sterilizing the ready-to-inject epinephrine composition... The complaint does not provide specific detail on the manufacturing process but alleges the final product infringes the claims. ¶50 col. 4:37-41
...wherein the ready-to-inject epinephrine composition is substantially antioxidant-free and has, after storage of at least one month, total impurities of equal or less than 0.7% and equal or less than 4% S-isomer content. The Proposed sNDA Product is alleged to be a formulation that infringes, which implies it will meet the claimed stability and impurity profile. ¶50 col. 4:42-49

’280 Patent Infringement Allegations

Claim Element (from Independent Claim 1) Alleged Infringing Functionality Complaint Citation Patent Citation
A sterile storage stable ready-to-inject epinephrine composition, comprising: an aqueous pharmaceutically acceptable carrier containing epinephrine; wherein the epinephrine is present in the ready-to-inject epinephrine composition at a concentration of equal or less than 0.07 mg/ml... Defendant's Proposed sNDA Product contains epinephrine at a concentration of 16 mcg/mL (0.016 mg/mL) in an aqueous carrier (0.9% Sodium Chloride Injection). ¶42 col. 28:1-6
...wherein at least about 90 mol % of the epinephrine is an R-isomer; The Proposed sNDA Product is alleged to be covered by the claims, which requires this level of the R-isomer. ¶42 col. 28:7-8
...wherein the composition has a pH of between 3.0-4.7; The Proposed sNDA Product is alleged to be a formulation that infringes, implying it has a pH within the claimed range. ¶42 col. 28:9-10
...wherein the composition further comprises a metal ion chelator selected from the group consisting of a bicarboxylic acid...at a concentration of between about 1 and 50 µg/ml... The Proposed sNDA Product is alleged to be covered by the claims, which require a chelator in this class and concentration. ¶42 col. 28:11-16
...and wherein the composition has a total impurities concentration of equal to or less than 0.3% after storage of at least one month at 25° C. The Proposed sNDA Product is alleged to be a formulation that infringes, which implies it will meet the claimed stability and impurity profile. ¶42 col. 28:17-20

Identified Points of Contention

  • Evidentiary Questions: The central dispute will depend on evidence obtained in discovery. Key questions include: Does Defendant's manufacturing process for the Proposed sNDA Product practice all steps of the asserted method claims (e.g., of the ’719 patent)? Does the final composition of the Proposed sNDA Product, as manufactured, have a pH, chelator concentration, dissolved oxygen level, and impurity/isomer profile that falls within the ranges recited in the asserted composition claims (e.g., of the ’280 patent)?
  • Scope Questions: A likely point of contention will be the interpretation of quantitative claim limitations, particularly those modified by the term "about" (e.g., "between about 1 and 50 µg/ml"). The analysis will question whether Defendant's product, if its formulation is near the boundary of a claimed range, literally infringes or infringes under the doctrine of equivalents.

V. Key Claim Terms for Construction

"ready-to-inject" / "ready-to-administer"

  • Context and Importance: This term is central to the invention's purpose of providing a product that avoids the need for dilution at the point of care Compl. ¶37 Practitioners may focus on this term to distinguish the invention from prior art concentrated formulations. The dispute will question whether the term implies specific characteristics beyond simply being pre-diluted, such as being packaged in a specific type of container (e.g., an IV bag) or having a particular volume.
  • Intrinsic Evidence for Interpretation:
    • Evidence for a Broader Interpretation: The claims themselves do not specify a particular container type or volume, suggesting any formulation not requiring dilution could be "ready-to-inject" ’646 Patent, claim 1
    • Evidence for a Narrower Interpretation: The specification repeatedly discusses the invention in the context of flexible infusion bags (IV bags) or blow-fill-seal containers with volumes of 100 mL or more, which could support a narrower construction limited to such formats ’646 Patent, col. 9:1-4 ’646 Patent, col. 9:26-30 The patents also define "ready-to-administer" as formulations that "can be administered to a patient in need thereof without prior dilution" ’646 Patent, col. 10:5-12, which could be argued to set a functional, rather than structural, limit.

"substantially antioxidant-free"

  • Context and Importance: This term distinguishes the invention from prior art formulations that relied on antioxidants like sodium metabisulfite, which could cause allergic reactions Compl. ¶36 Practitioners may focus on this term because it is a key point of novelty. The dispute will revolve around the precise quantitative limit for what constitutes "substantially free."
  • Intrinsic Evidence for Interpretation:
    • Evidence for a Broader Interpretation: The term itself is qualitative, suggesting a flexible standard that may not require a complete absence of antioxidants.
    • Evidence for a Narrower Interpretation: The specification provides an explicit definition: "substantially free of antioxidants (i.e., do not include antioxidants in an amount effective to reduce degradation of total epinephrine by at least about 1% when stored over a period of at least three months at 25° C.+/-2° C.)" ’646 Patent, col. 8:60-67 This provides a specific functional test that could be used to argue for a narrow, defined meaning.

VI. Other Allegations

Indirect Infringement

The complaint alleges induced infringement, stating that Defendant's proposed product labeling will instruct healthcare providers to use the Proposed sNDA Product in a manner that directly infringes the patents-in-suit Compl. ¶52 Compl. ¶60 It further alleges contributory infringement Compl. ¶53 Knowledge and specific intent are alleged based on Defendant's submission of the sNDA and Paragraph IV Certification, which demonstrates awareness of the patents Compl. ¶54 Compl. ¶62

Willful Infringement

The complaint does not use the term "willful" but lays the groundwork for such a claim by alleging that Defendant had pre-suit knowledge of the patents-in-suit at the time it filed its sNDA Compl. ¶54 Compl. ¶62 Compl. ¶70 Compl. ¶78 Compl. ¶86 In the prayer for relief, Plaintiffs request a declaration that the case is "exceptional" and an award of attorneys' fees pursuant to 35 U.S.C. § 285, which is the statutory basis for enhanced damages in cases of egregious infringement Compl. p. 23

VII. Analyst’s Conclusion: Key Questions for the Case

This Hatch-Waxman case, initiated by a Second Amended Complaint, presents a focused dispute over a generic epinephrine formulation. The resolution will likely depend on the answers to three central questions:

  • A primary issue will be one of evidentiary alignment: Once the specifics of Defendant's formulation and manufacturing process are revealed in discovery, will the product's characteristics—including its pH, chelator type and concentration, S-isomer content, and total impurity levels after sterilization and storage—fall squarely within the numerical ranges defined in the asserted claims?
  • A second core issue will be one of claim construction: How will the court interpret key quantitative limitations, such as concentration ranges prefixed by "about," and qualitative terms like "substantially antioxidant-free"? The construction of these terms will define the scope of infringement and be critical in determining whether Defendant's product, particularly if its formulation lies near the boundaries of the claimed ranges, infringes.
  • A third, unstated but implicit, question relates to validity: Defendant's Paragraph IV certification suggests it will challenge the patents' validity. The key question for the court will be whether the claimed combination of elements (a specific pH range, a low concentration of a chelator, antioxidant-free) in a ready-to-use epinephrine formulation represents a non-obvious advance over the prior art.